CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults Meghann Wheelera, Julie Williams Mertena, Benjamin T Gordonb, and Hanadi Hamadic SUBSTANCE USE & MISUSE, 2020, VOL. 55, NO. 7, 1138–1145 doi : 10.1080/10826084.2020.1729201 ABSTRACT Background : Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing. Purpose/Objectives : This study aims to explore cannabidiol (CBD) knowledge, attitudes, and use among young adults. Methods : The anonymous 36-item survey [...]
Lire la suiteDevelopment of Ketamine Administration as a Treatment for Chronic PTSD Abigail B. Collins, BS; Sarah B. Rutter, MA; and Adriana Feder, MD Psychiatric Annals, 2020, 50, (2), 68-76. doi : 10.3928/00485713-20200109-01 ABSTRACT Posttraumatic stress disorder (PTSD) is a highly prevalent, chronic, and dis-abling condition for which currently available pharmacotherapies are insuf-ficiently effective. Ketamine, which is a glutamate N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising and rapid-act-ing novel treatment intervention for this disorder. Findings from a proof-of-concept, randomized, controlled cross-over study of single-dose intravenous ketamine administration (compared to single-dose midazolam) in patients with chronic PTSD suggest that ketamine is associated with rapid improvement in [...]
Lire la suiteHow Cannabis-Based Therapeutics Could Help Fight COVID Inflammation Liz Scherer Medscape.com, November 03, 2020 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing). There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of [...]
Lire la suitePsilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape.com, November 05, 2020 Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding and really sets the [...]
Lire la suiteUse of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia Nathan A. Gillespie, Kenneth S. Kendler JAMA Psychiatry, Published online November 4, 2020 Cohort studies and meta-analyses have documented a robust association between cannabis use, heavy use, and misuse with future risk of schizophrenia.1-3 Despite adjusting for covariates, including current psychotic symptoms, other psychopathology, and social integration,(1) the ability of these models to determine the degree to which cannabis causes schizophrenia is limited and dependent on their ability to capture all relevant confounders. When evaluating efforts to reduce cannabis use as a means of [...]
Lire la suiteEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder. A Randomized Clinical Trial Alan K. Davis, PhD; Frederick S. Barrett, PhD; Darrick G. May, MD; Mary P. Cosimano, MSW; Nathan D. Sepeda, BS; Matthew W. Johnson, PhD; Patrick H. Finan, PhD; Roland R. Griffiths, PhD JAMA Psychiatry, 2020, E1-E9. doi : 10.1001/jamapsychiatry.2020.3285 IMPORTANCE : Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. OBJECTIVE : To investigate the effect of psilocybin [...]
Lire la suitePsychedelics as a Treatment for Alzheimer’s Disease Dementia Simon Andrew Vann Jones and Allison O’Kelly Cornwall Partnership NHS Foundation Trust, Liskeard, United Kingdom Frontiers in Synaptic Neuroscience, August 2020 | Volume 12 | Article 34 doi : 10.3389/fnsyn.2020.00034 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD), coupled with anecdotal reports of cognitive benefits from micro-dosing, suggests that they may have a therapeutic role in a range of psychiatric and neurological conditions due to their potential to stimulate neurogenesis, provoke neuroplastic [...]
Lire la suiteMinor Cannabinoids of Cannabis sativa L. Fabian Thomas & Oliver Kayser Journal of Medical Science, 2019, 88, (3), 141-149. Doi : 10.20883/jms.367 ABSTRACT Cannabinoids from Cannabis sativa L. play an important role as natural products in clinics. The major cannabinoids compromise tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) and its decarboxylated analogs. In this review, we focus on often neglected minor cannabinoids and discuss biosynthetic and chemical degradation routes to other neglected cannabinoids in Cannabis sativa starting from THCA, CBDA and cannabichromenic acid (CBCA). Based on the literature, patents and scientific reports, essential routes for the chemical modifi cation of cannabinoids are discussed to explain [...]
Lire la suiteCannabis sativa L. CANNABACEAE Rainer W. Bussmann, Ketevan Batsatsashvili, Zaal Kikvidze, Narel Y. Paniagua-Zambrana, Manana Khutsishvili, Inesa Maisaia, Shalva Sikharulidze, and David Tchelidze © Springer Nature Switzerland AG 2020 in K. Batsatsashvili et al. (eds.), Ethnobotany of the Mountain Regions of Far Eastern Europe, Ethnobotany of Mountain Regions, doi : 10.1007/978-3-030-28940-9_33 Synonyms : Cannabis sativa L., Cannabis chinense Delile, Cannabis indica Lam, Cannabis sativa var. indica (Lam.) E. Small & Cronquist R. Local Names : Georgian : კანაფი (k’anapi); ქან (qan) (Grossheim 1952; Ketskhoveli et al. 1971–2011; Makashvili 1991; Fedorov 1984); English : Cannabis Botany and Ecology Annual; stems 50–150 cm, covered with appressed hairs; leaves long petioled, [...]
Lire la suiteResearch Progress of the Antiviral Bioactivities of Natural Flavonoids Lin Wang · Junke Song · Ailin Liu · Bin Xiao · Sha Li · Zhang Wen · Yang Lu · Guanhua Du Natural Products and Bioprospecting, 2020, 10, 271–283 doi : 10.1007/s13659-020-00257-x Abstract Flavonoids are now considered as an indispensable component in a variety of nutraceutical and pharmaceutical applications. Most recent researches have focused on the health aspects of flavonoids for humans. Especially, different flavonoids have been investigated for their potential antiviral activities, and several natural flavonoids exhibited significant antiviral properties both in vitro and in vivo. This review provides a survey of the literature [...]
Lire la suite